DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2011/0118227 A1 White Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2011/0118227 A1 White Et Al US 2011 0118227A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0118227 A1 White et al. (43) Pub. Date: May 19, 2011 (54) METHODS FOR THE TREATMENT OF Pat. No. 7,799.769, which is a continuation of appli FBROMYALGA AND CHRONIC EATGUE cation No. 10/464,310, filed on Jun. 18, 2003, now SYNDROME abandoned. (75) Inventors: Hillary D. White, S. Pomfret, VT Publication Classification (US); Robert Gyurik, Exeter, NH (51) Int. Cl. (US) A6II 3/568 (2006.01) A6IP 29/00 (2006.01) (73) Assignee: White Mountain Pharma, Inc., A6IP5/26 (2006.01) New York, NY (US) GOIN 33/74. (2006.01) (21) Appl. No.: 12/949,644 (52) U.S. Cl. ........................................ 514/179; 435/7.92 (22) Filed: Nov. 18, 2010 (57) ABSTRACT The invention relates to methods for the treatment of fibro Related U.S. Application Data myalgia and chronic fatigue syndrome by administration of a (63) Continuation-in-part of application No. 12/837,310, transdermally applied androgen composition. The treatment filed on Jul. 15, 2010, which is a continuation of appli is both safe and effective for treating fibromyalgia-related cation No. 11/303,813, filed on Dec. 16, 2005, now pain and fatigue, as well as chronic fatigue syndrome. Patent Application Publication May 19, 2011 Sheet 1 of 33 US 2011/O118227 A1 A Total Testosterone Day 1 3.5 - - FG. A ME OF DAY 35 Awamwawraarvavarawawawasawawawawawayawawawasawa-ra-Mawraa-raB. Total Testosterone Day 28 F.G. B. e & o c. c. o c. Co 9 S S S E & & -e-07 TME OF DAY -o-018 C, Tota Testosteroie d1(circles), d28(squares), Meant SE, n=12 3.5 fore F.G. C TMEO DAY Patent Application Publication May 19, 2011 Sheet 2 of 33 US 2011/0118227 A1 8 A. Free Testosterone Day 1 7 6 - 5 54O) - H - - - - - - - - - - - - - - - - - - - - -1- - - - - - - FIG. 2A S3 H-2 22 Seetzssesses ll. 1 O - A . C C C C C C Cld Cd O cad O CO d o Cld C C C C C C CD O O. O. O. d O cos co s () is cd do o d\ c ( s. co do wns w- v- w w CN CN 8 7 6 5 - S 4 FIG. 2B 2 3 St - * - 1 O - 53(O CO So SCr Sw S() SCO &C 3N C CN S (O CO --e-018, - - - - v - re- (N on C. Free Testosterone 5 d1 (circles), d28(squares) Mean it SE 4 33 E FIG. 2C 22 St 1 Patent Application Publication US 2011/O118227 A1 ?:?********************************* Tender Point (SEM) FIG. 4 Patent Application Publication May 19, 2011 Sheet 5 of 33 US 2011/O118227 A1 A. P Walue Muscle Pain Fe OO1 Stiffness m I O.04 Fatigue upon Day 1 awakening O Day 28 - FIG. 5A Libido OOO2 O 2 4 6 8 1O B. PValue Day 1 D Day 28 FIG.SB WAS SCale Patent Application Publication May 19, 2011 Sheet 6 of 33 US 2011/0118227 A1 Subject 1 Time (hr) -- T Day 0 -C-T Day 28 - - A - - Fi Day 0 - - -X Ff Day 28 FIG. 6A Subject 2 Time (hr) --Ti Day 0 -O-T. Day 28 - - - A -- F Day 0 - - -x FTDay 28 F.G. 6B Patent Application Publication May 19, 2011 Sheet 7 of 33 US 2011/0118227 A1 Subject 3 Time (hr) -- Day 0 - - TT Day 28 - - -A - FTDay 0 - - -x -- FT Day 28 F.G. 6C 5 4.5 Y -E 4 -5 g 3.5 3. 5 3 3 is 2.5 s 1.5 s CX C - 0.5 U Time (hi) --T T Day 0 -O-T. Day 28 - - - A -- FT Day 0 - - -K - - Ft Day 28 F.G. 6D Patent Application Publication May 19, 2011 Sheet 8 of 33 US 2011/O118227 A1 Subject 6 1. S. S S. g 3 S D C O C O c time (h) --T Day 0 ---TDay 28 - - A - - F Day 0 - - -x - - FDay 28 F.G. 6E Subject 7 8 8 7 2K - - - - - - - - - - - - ........ 7 A -X ...? a S 6 xe, KYK ---. &: 6 S a , s A. d 5 A, A. s S. 5 X, as 3 4. ASA - A SE 4 s St A. * ES st is 3 ar 3 S. 8 2 --- 28 c 1 - 1st -0-0--has is reo. 1 1 , O 5 10 15 2O 25 Time (hr) --TT Day () --TDay 28 - - -A - - Fi Day 0 - - -x - - F Day 28 F.G. 6F Patent Application Publication May 19, 2011 Sheet 9 of 33 US 2011/O118227 A1 Subject 8 Time (hr) --Ti Day 0 ---TT Day 28 - - - A -- FTDay 0 - - -X - F Day 28 FIG. 6G Subject 9 3.5 - -axis O O 3.5 ar 3 3 1. K. g 2.5 K w X X -ca 2.5 3. MN K - Y - - - - - - - - . es5 2 A- As& thr-A-sist ' ' ' ' . <-2 5 re-Kg2/ is SS----A --see--- a-- 1.5 gE - A. ------ m --rocor-ra------ar-r-r- 1 OO ru8. " is Cd 0.5i t- orroo ar 0.5 - r A o re- - O 5 Q 15 2 25 Time (hr) -- TT Day O -O-TT Day 28 - - -A - - Ft Day 0 - - -x - Ft Day 28 F.G. 6H Patent Application Publication May 19, 2011 Sheet 10 of 33 US 2011/O118227 A1 Subject 10 Time (hr) --Ti Day O --TDay 28 - - - A - - Ft Day ( - - -K - - F Day 28 F.G. 6 Subject 11 Time (hr) -- T Day O --Ti Day 28 - - A - FTDay 0 - - x - F Day 28 FG, 6. Patent Application Publication May 19, 2011 Sheet 11 of 33 US 2011/O118227 A1 Subject 12 Time (hr) -- Day 0 -O-T. Day 28 - - - A - - FTDay 0 - - x - FTDay 28 F.G. 6K Subject 13 3, 5 time (hr) -- Day O -- i r Day 28 - - -A - - FTDay 0 - - -k FTDay 28 F.G. 6 Patent Application Publication May 19, 2011 Sheet 12 of 33 US 2011/O118227 A1 Wear Walues with Confidence intervals 2 5 Cmin, Cmin, Day 1 Day 28 F.G. 6M W Patent Application Publication May 19, 2011 Sheet 13 of 33 US 2011/O118227 A1 Fibromyalgia Study, Preliminary Patient Questionnaire Name: Age. Date of birth: SS# Address: If you are enrolled in this study, your address and social security number are required for lS to pay you. Daytime Telephone Number: Patient code: Yes No Please the laterior the is a How tall are you? How many pounds do you weigh? Have you been diagnosed with Fibromyalgia Syndrome? urrrm Do you have widespread pain all over? (above/below waist, right/left sides) Are you frequently fatigued? Have you had your ovaries removed? lf yes, please give the date of your Surgery Are you on hormone therapy? If yes, what hormones: Are you willing to discontinue your hormone therapy for 6 months? When was your last menstrual period? Do you have undiagnosed vaginal bleeding? Do you Smoke? If yes, how many cigarettes a day? Do you drink alcohol? If yes, how much a day, a week? Do you have high blood pressure, cardiovascular disease, liver or kidney disease, cancer, diabetes? Specify: Do you have any skin diseases? Specify: Do you take St. John’s wort, ginger root, antidepressants? If yes, are you willing to stop taking them for 6 months? | Are you willing to exercise 20 minutes a day, 5 days a week? Thank you for answering this questionnaire. You may explain any responses on the back. FIG. 7 Patent Application Publication May 19, 2011 Sheet 14 of 33 US 2011/O118227 A1 Fibromyalgia Study. Testosterone Replacement Therapy vs Placebo Physician Questionnaire Eligibility Criteria Form Eligibility Criteria Patient Code Number Patient Initials .......... Prelim TP Exam Date Physician (initials): A. Laboratory tests for eligibility criteria Screen visit day 1 12 weeks 24 weeks Dale blood drawn (mm/dd/yy) f / f / f / --- l. Testosterone: ................................ 2. EStradiol: ....................................... 3. Lipid Profile. a total cholesterol ............................ b. HDL ......................................... C. D. ...................... 4. Liver Function Tests (LFT): a. All-T (Alanine aminotransferase) ammurum- o b. ALP (Alkaline phosphatase) ........ c. AST (Asp aminotransferase) ........ d. albumin ......................................... e. Til . f. DBill ............................................... 5. Kidney function: a. BUN . --- ---------- --mm b. creatinine ...................................... am ------------- --------- 6. FSH. --mm 7. CBC Flemoglobin.......................... ------------- - ----- B. Informed written consent obtained? Yes | No C. Does the patient express any Symptoms of chronic fatigue? D. Does the patient express difficulty obtaining restorative sleep? FIG. 8 Patent Application Publication May 19, 2011 Sheet 15 of 33 US 2011/O118227 A1 Fibromyalgia Study. Testosterone Replacement Therapy vs Placebo Dose Coordinato Serum Testosterone Values Patient Code Number... Patient Initials ............. Prelim TP Exam Date . f f Circle: Placebo Testosterone : Dose Coordinator (initials): 4 weeks 8 weeks l2 weeks l 6 weeks 20 weeks 24 weeks Date blood drawn f / A / f / f f f f / / A. Total Testosterone: B. Free Testosterone: Based on Free Testosterone: Step up packet? f / f / f / f / f f f / (if LOW free T s l.9pg/mL, date patient started change in Study gel dose) Step down packet? / / f / f / f / f f f f f (if High free T P 3.3 pg/mL, date patient started change in Study gel dose) FIG. 9 Patent Application Publication May 19, 2011 Sheet 16 of 33 US 2011/O118227 A1 SJLNIOdRIGH(INGHJ,SWH:JAVNOIAVOIJVÍ?TIÞÆGIAVVIOISÄHAI Patent Application Publication May 19, 2011 Sheet 17 of 33 US 2011/O118227 A1 Fibromyalgia Study. TestosterOne Replacement Therapy vs Placebo Physician General Health Form Patient Code Number Patient Initials .......... Exam Date ................. / / Circle One: Screening Visit 2 Week 2 Week 24 Physician (initials): LUNGS: CARDIOVASCULAR: ABDOMINAL: EDEMA: HEENT (Head Eyes Ears Nose Throat).
Load more

Recommended publications
  • Human DHEA ELISA Kit (ARG80949)
    Product datasheet [email protected] ARG80949 Package: 96 wells Human DHEA ELISA Kit Store at: 4°C Summary Product Description ARG80949 DHEA ELISA Kit is an Enzyme Immunoassay kit for the quantification of DHEA in human serum and plasma (EDTA). Tested Reactivity Hu Tested Application ELISA Target Name DHEA Sensitivity 0.07 ng/ml Sample Type Serum and plasma (EDTA). Standard Range 0.3 - 30 ng/ml Sample Volume 25 μl Application Instructions Assay Time 1 h (RT/shaker), 30 min (dark) Properties Form 96 well Storage instruction Store the kit at 2-8°C. Keep microplate wells sealed in a dry bag with desiccants. Do not expose test reagents to heat, sun or strong light during storage and usage. Please refer to the product user manual for detail temperatures of the components. Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Background Dehydroepiandrosterone (DHEA; androstenolone; 3b-hydroxy-5-androsten-17-one) is a C19 steroid produced in the adrenal cortex and, to a lesser extent, gonads. DHEA serves as a precursor in testosterone and estrogen synthesis. Due to the presence of a 17-oxo (rather than hydroxyl) group, DHEA has relatively weak androgenic activity, which has been estimated at ~10% that of testosterone. However in neonates, peripubertal children and in adult women, circulating DHEA levels may be several- fold higher than testosterone concentrations, and rapid peripheral tissue conversion to more potent androgens (androstenedione and testosterone) and estrogens may occur. Moreover, DHEA has relatively low affinity for sex-hormone binding globulin. These factors may enhance the physiologic biopotency of DHEA.
    [Show full text]
  • Oxysterols Block Transport by Binding to Insig
    Sterol-regulated transport of SREBPs from FEATURE ARTICLE endoplasmic reticulum to Golgi: Oxysterols block transport by binding to Insig Arun Radhakrishnan*, Yukio Ikeda*, Hyock Joo Kwon†, Michael S. Brown*‡, and Joseph L. Goldstein*‡ Departments of *Molecular Genetics and †Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390 This Feature Article is part of a series identified by the Editorial Board as reporting findings of exceptional significance. Edited by Randy Schekman, University of California, Berkeley, CA, and approved February 20, 2007 (received for review January 31, 2007) Cholesterol synthesis in animals is controlled by the regulated trans- liberate a transcriptionally active fragment, allowing it to enter the port of sterol regulatory element-binding proteins (SREBPs) from the nucleus (1). There, the SREBP activates transcription of genes endoplasmic reticulum to the Golgi, where the transcription factors encoding 3-hydroxy-3-methylglutaryl CoA reductase (HMGR) and are processed proteolytically to release active fragments. Transport is all of the other enzymes involved in the synthesis and uptake of inhibited by either cholesterol or oxysterols, blocking cholesterol cholesterol (14). synthesis. Cholesterol acts by binding to the SREBP-escort protein SREBPs are transported from ER to Golgi through the action of Scap, thereby causing Scap to bind to anchor proteins called Insigs. an escort protein called Scap, which forms a complex with SREBPs Here, we show that oxysterols act by binding to Insigs, causing Insigs immediately after their synthesis (3). Scap contains a binding site to bind to Scap. Mutational analysis of the six transmembrane helices for COPII proteins, which cluster the Scap⅐SREBP complex into of Insigs reveals that the third and fourth are important for Insig’s COPII-coated vesicles (15).
    [Show full text]
  • Pros and Cons Controversy on Molecular Imaging and Dynamic
    Open Access Archives of Biotechnology and Biomedicine Research Article Pros and Cons Controversy on Molecular Imaging and Dynamics of Double- ISSN Standard DNA/RNA of Human Preserving 2639-6777 Stem Cells-Binding Nano Molecules with Androgens/Anabolic Steroids (AAS) or Testosterone Derivatives through Tracking of Helium-4 Nucleus (Alpha Particle) Using Synchrotron Radiation Alireza Heidari* Faculty of Chemistry, California South University, 14731 Comet St. Irvine, CA 92604, USA *Address for Correspondence: Dr. Alireza Abstract Heidari, Faculty of Chemistry, California South University, 14731 Comet St. Irvine, CA 92604, In the current study, we have investigated pros and cons controversy on molecular imaging and dynamics USA, Email: of double-standard DNA/RNA of human preserving stem cells-binding Nano molecules with Androgens/ [email protected]; Anabolic Steroids (AAS) or Testosterone derivatives through tracking of Helium-4 nucleus (Alpha particle) using [email protected] synchrotron radiation. In this regard, the enzymatic oxidation of double-standard DNA/RNA of human preserving Submitted: 31 October 2017 stem cells-binding Nano molecules by haem peroxidases (or heme peroxidases) such as Horseradish Peroxidase Approved: 13 November 2017 (HPR), Chloroperoxidase (CPO), Lactoperoxidase (LPO) and Lignin Peroxidase (LiP) is an important process from Published: 15 November 2017 both the synthetic and mechanistic point of view. Copyright: 2017 Heidari A. This is an open access article distributed under the Creative
    [Show full text]
  • Insulin and Estrogen Independently and Differentially Reduce Macronutrient Intake in Healthy Men
    Downloaded from https://academic.oup.com/jcem/article-abstract/103/4/1393/4801230 by GSF-Forschungszentrum fuer Umwelt und Gesundheit GmbH - Zentralbibliothek user on 21 December 2018 CLINICAL RESEARCH ARTICLE Insulin and Estrogen Independently and Differentially Reduce Macronutrient Intake in Healthy Men Rosemarie Krug,1 Linda Mohwinkel,2 Bernhard Drotleff,3 Jan Born,1,4,5 and Manfred Hallschmid1,4,5 1Department of Medical Psychology and Behavioral Neurobiology, University of Tubingen, ¨ 72076 T¨ubingen, Germany; 2Department of Neuroendocrinology, University of Lubeck, ¨ 23538 Lubeck, ¨ Germany; 3Institute of Pharmaceutical Sciences, University of Tubingen, ¨ 72076 Tubingen, ¨ Germany; 4German Center for Diabetes Research (DZD), 85764 Munchen-Neuherberg, ¨ Germany; and 5Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tubingen ¨ (IDM), 72076 T¨ubingen, Germany Context: Insulin administration to the central nervous system inhibits food intake, but this effect has been found to be less pronounced in female compared with male organisms. This sex-specific pattern has been suggested to arise from a modulating influence of estrogen signaling on the insulin effect. Objective: We assessed in healthy young men whether pretreatment with transdermal estradiol in- teracts with the hypophagic effect of central nervous insulin administration via the intranasal pathway. Design, Setting, Participants, and Intervention: According to a 232 design, two groups of men (n = 16 in each group) received a 3-day transdermal estradiol (100 mg/24 h) or placebo pretreatment and on two separate mornings were intranasally administered 160 IU regular human insulin or placebo. Main Outcome Measures: We assessed free-choice ad libitum calorie intake from a rich breakfast buffet and relevant blood parameters in samples collected before and after breakfast.
    [Show full text]
  • Physiological Aspects of Steroids in Pollen of Pinus Elliotti Engelm
    PHYSIOLOGICAL ASPECTS OF STEROIDS IN POLLEN OF Pinus el 1 i otti Engelm. by JOSEPHUS KARL PETER A DISSERTATION PRESENTED TO THE GRADUATE COUNCIL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY UNIVERSITY OF FLORIDA 1979 ACKNOWLEDGEMENTS I wish to express my sincere appreciation to Dr. Ray E. Goddard, chariman of my supervisory committee, for his council during my graduate program and his aid in preparation of this manuscript. Special thanks are due to Dr. R. Hilton Biggs, member of my supervisory committee, for his moral support, his valuable advice during experimentation, and his assistance in preparation of the dissertation. Much apprecia- tion is also expressed to Dr. Charles A. Hollis, Dr. Leon A. Garrard, and Dr. Richard C. Smith for their criticism and aid in improving this manuscript. I am mostly indebted to the late Dr. Robert G. Stanley whose friendship, moral support and unabated intellectual stimulation was of utmost importance during my graduate as well as undergraduate years. I am particularly grateful to Dr. Roy W. King, Mr. Joel E. Smith, Mrs. Sarah G. Mesa, Dr. Cu Van Vu, Mrs. Alma Lugo, Ms Bonnie Turner, and Mr. Dennis Peacock who assisted at various stages through the research and preparation of the manuscript. Finally, I am most sincere in the appreciation and gratefulness to my wife Rita, whose encouragement, patience and moral support made my dissertation possible. To Rita I wish to dedicate this manuscript. ii TABLE OF CONTENTS Page ACKNOWLEDGEMENTS ii
    [Show full text]
  • Processes for the Preparation Of
    (19) TZZ Z_T (11) EP 2 999 708 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12P 33/16 (2006.01) C07J 1/00 (2006.01) 22.08.2018 Bulletin 2018/34 (86) International application number: (21) Application number: 14801828.6 PCT/IB2014/061590 (22) Date of filing: 21.05.2014 (87) International publication number: WO 2014/188353 (27.11.2014 Gazette 2014/48) (54) PROCESSES FOR THE PREPARATION OF DEHYDROEPIANDROSTERONE AND ITS INTERMEDIATES VERFAHREN ZUR HERSTELLUNG VON DEHYDROEPIANDROSTERON UND DESSEN ZWISCHENPRODUKTEN PROCÉDÉS DE PRÉPARATION DE DÉSHYDROÉPIANDROSTÉRONE ET DE SES INTERMÉDIAIRES (84) Designated Contracting States: • DAHANUKAR, Vilas AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Hyderabad 500008 (IN) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Bates, Philip Ian Reddie & Grose LLP (30) Priority: 21.05.2013 IN 2214CH2013 The White Chapel Building 10 Whitechapel High Street (43) Date of publication of application: London E1 8QS (GB) 30.03.2016 Bulletin 2016/13 (56) References cited: (73) Proprietor: Dr. Reddy’s Laboratories Ltd. EP-A2- 0 133 995 US-A- 4 791 057 500 034 Andhra Pradesh (IN) US-A- 5 604 213 US-B1- 6 284 750 US-B2- 8 227 208 (72) Inventors: • FRYSZKOWSKA, Anna • MARGARET G WARD ET AL: "Reversibility of Cambridge CB4 1GF (GB) Steroid Delta-Isomerase II. THE REACTION • QUIRMBACH, Michael Siegfried SEQUENCE IN THE CONVERSION OF 4054 Basel (CH) ANDROST-4-ENE-3,17-DIONE TO 3-HY • GORANTLA, Srikanth Sarat Chandra DROXYANDROST-5-EN-17-ONE BY SHEEP Hyderabad 500047 ADRENAL MICROSOMES", THE JOURNAL OF Andhra Pradesh (IN) BIOLOGICAL CHEMISTRY, vol.
    [Show full text]
  • Normal Human Adrenals *
    Journal of Clinical Investigation Vol. 44, No. 1, 1965 C.902 Steroids and Some of Their Precursors in Blood from Normal Human Adrenals * RALPH G. WIELAND, CONSTANCE DE COURCY, RICHARD P. LEVY, ANTONIA P. ZALA, AND H. HIRSCHMANN (From the Department of Medicine, Western Reserve University and University Hospitals, Cleveland, Ohio) The ready response of the main urinary 11- Methods deoxy- 17-ketosteroids to adrenal suppression and Patients. The subjects studied were five women (I.A., adrenal stimulation leaves no doubt that a con- M.R., C.B., M.M., and R.R.) and three men (J.J., L.W., siderable fraction of urinary androsterone (3a- and F.B.). Their ages and serial numbers are given in hydroxy-5a-androstan-17-one), 5,8-androsterone Table III. R.R. had hirsutism but normal ovulatory (3ca-hydroxy-5/8-androstan-17-one), and andros- menses and F.B. had diabetes. There was no other evi- dence of endocrinologic disease or hepatic dysfunction in tenolone (3,8-hydroxyandrost-5-en-17-one, dehy- any of these subjects. The patients fasted on the morn- droepiandrosterone) must be derived from adrenal ing of the procedure. Secobarbital (100 mg orally) was precursors. However, when adrenal vein blood given at 8 a.m., and 50 mg meperidine hydrochloride was was examined for such compounds, no consistent given subcutaneously just before the catheterization,' pattern emerged (3-9) ; therefore the identity of which was usually done between 10 a.m. and noon es- sentially in the manner performed by Cranston (5). the precursors remained in doubt. The presence The location of the catheter was ascertained by veno- of androstenedione (androst-4-ene-3,17-dione), gram.
    [Show full text]
  • Steroidní Látky V Odpadních Vodách – Výskyt, Metody Vzorkování a Analytického Stanovení
    MASARYKOVA UNIVERZITA V BRN Ě PŘÍRODOV ĚDECKÁ FAKULTA RECETOX VÝZKUMNÉ CENTRUM PRO CHEMII ŽIVOTNÍHO PROST ŘEDÍ A EKOTOXIKOLOGII STEROIDNÍ LÁTKY V ODPADNÍCH VODÁCH – VÝSKYT, METODY VZORKOVÁNÍ A ANALYTICKÉHO STANOVENÍ Lucie Langová Bakalá řská práce Brno, Česká republika, rok 2008 MASARYKOVA UNIVERZITA V BRN Ě PŘÍRODOV ĚDECKÁ FAKULTA RECETOX VÝZKUMNÉ CENTRUM PRO CHEMII ŽIVOTNÍHO PROST ŘEDÍ A EKOTOXIKOLOGII STEROIDNÍ LÁTKY V ODPADNÍCH VODÁCH – VÝSKYT, METODY VZORKOVÁNÍ A ANALYTICKÉHO STANOVENÍ Lucie Langová Bakalá řská práce Vedoucí: doc. RNDr. Zden ěk Šimek, CSc. Brno, Česká republika, rok 2008 2 Prohlášení Prohlašuji, že jsem tuto bakalářskou práci vypracovala samostatn ě s použitím uvedené literatury. V Brn ě dne 19.5. 2008 Lucie Langová Pod ěkování Cht ěla bych pod ěkovat doc.RNDr. Zdeňku Šimkovi za odborné vedení a cenné rady, dále d ěkuji Mgr. Klá ře Hilscherové, PhD. za laskavé zap ůjčení článk ů. 3 Obsah 1. Úvod ......................................................................................................................................... 5 2. Seznam zkratek ....................................................................................................................... 7 3.Rozd ělení steroidních látek ..................................................................................................... 8 3.1 P řírodní steroidní látky....................................................................................................... 8 3.2 Syntetické steroidní látky..................................................................................................
    [Show full text]
  • Dehydroepiandrosterone Or Testosterone) for Women Undergoing Assisted Reproduction (Review)
    Cochrane Database of Systematic Reviews Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction (Review) Nagels HE, Rishworth JR, Siristatidis CS, Kroon B Nagels HE, Rishworth JR, Siristatidis CS, Kroon B. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. Cochrane Database of Systematic Reviews 2015, Issue 11. Art. No.: CD009749. DOI: 10.1002/14651858.CD009749.pub2. www.cochranelibrary.com Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 6 OBJECTIVES ..................................... 7 METHODS ...................................... 7 Figure1. ..................................... 9 Figure2. ..................................... 10 Figure3. ..................................... 11 RESULTS....................................... 13 Figure4. ..................................... 16 Figure5. ..................................... 17 Figure6. ..................................... 19 Figure7. ..................................... 21 ADDITIONALSUMMARYOFFINDINGS . 22 DISCUSSION ..................................... 25 AUTHORS’CONCLUSIONS . 26 ACKNOWLEDGEMENTS . 26 REFERENCES ....................................
    [Show full text]
  • Hormonal Effects of Prohormones Novel Approaches Towards Effect Based Screening in Veterinary Growth Promoter Control
    Hormonal effects of prohormones Novel approaches towards effect based screening in veterinary growth promoter control Jeroen C.W. Rijk Thesis committee Thesis supervisors Prof. dr. M.W.F. Nielen Professor of Detection of Chemical Food Contaminants Wageningen University Prof. dr. ir. I.M.C.M. Rietjens Professor of Toxicology Wageningen University Thesis co-supervisors Dr. M.J. Groot Veterinary Pathologist RIKILT - Institute of Food Safety, Wageningen UR Dr. A.A.C.M. Peijnenburg Head of Toxicology and Effect analysis group RIKILT - Institute of Food Safety, Wageningen UR Other members: Prof. B. Le Bizec, LABERCA - ONIRIS, Nantes, France Dr. W.G.E.J. Schoonen, MSD, Oss Prof. dr. J. Fink-Gremmels, Utrecht University Prof. dr. M.A. Smits, Wageningen University This research was conducted under the auspices of the Graduate School VLAG. Hormonal effects of prohormones Novel approaches towards effect based screening in veterinary growth promoter control Jeroen C.W. Rijk Thesis Submitted in fulfillment of the requirements for the degree of doctor at Wageningen University by the authority of the Rector Magnificus Prof. dr. M.J. Kropff, in the presence of the Thesis Committee appointed by the Academic Board to be defended in public on Friday 3 December 2010 at 11 a.m. in the Aula. Jeroen C.W. Rijk Hormonal effects of prohormones Novel approaches towards effect based screening in veterinary growth promoter control 208 pages Thesis Wageningen University, Wageningen, NL (2010) ISBN 978-90-8585-819-5 Abstract Within the European Union the use of growth promoting agents in cattle fattening is prohibited according to Council Directive 96/22/EC.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Dehydroepiandrostero ne Item No. 15728 CAS Registry No.: 53-43-0 Formal Name: 5-androsten-3β-ol-17-one Synonyms: Androstenolone, trans-Dehydroandrosterone, O DHEA, Diandrone, NSC 9896, Prasterone, Psicosterone H MF: C19H28O2 FW: 288.4 H H Purity: ≥98% Stability: ≥2 years at -20°C HO Supplied as: A crystalline solid Laboratory Procedures For long term storage, we suggest that dehydroepiandrostero ne (DHEA) be stored as supplied at -20°C. It should be stable for at least two years. DHEA is supplied as a crystalline solid. A stock solution may be made by dissolving the DHEA in the solvent of choice. DHEA is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of DHEA in these solvents is approximately 10, 15, and 25 mg/ml, respectively. DHEA is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, DHEA should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. DHEA has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Description Dehydroepiandrosterone (DHEA) is an endogenous steroid hormone that is secreted primarily by the adrenal gland and is the most abundant sex steroid.1-3 Metabolites of DHEA include androstenedione (Item No. ISO60161), which subsequently may be metabolized to testosterone (Item Nos. ISO60154 | 15645) or estrone (Item Nos. ISO60165 | 10006485), which is an estradiol (Item Nos.
    [Show full text]
  • Steroidogenesis in the Green Anole Lizard Brain and Gonad
    Minnesota State University, Mankato Cornerstone: A Collection of Scholarly and Creative Works for Minnesota State University, Mankato All Graduate Theses, Dissertations, and Other Graduate Theses, Dissertations, and Other Capstone Projects Capstone Projects 2017 Steroidogenesis in the Green Anole Lizard Brain and Gonad Christine Peek Minnesota State University Follow this and additional works at: https://cornerstone.lib.mnsu.edu/etds Part of the Genetics Commons, Molecular Biology Commons, and the Neurosciences Commons Recommended Citation Peek, C. (2017). Steroidogenesis in the Green Anole Lizard Brain and Gonad [Master’s thesis, Minnesota State University, Mankato]. Cornerstone: A Collection of Scholarly and Creative Works for Minnesota State University, Mankato. https://cornerstone.lib.mnsu.edu/etds/736/ This Thesis is brought to you for free and open access by the Graduate Theses, Dissertations, and Other Capstone Projects at Cornerstone: A Collection of Scholarly and Creative Works for Minnesota State University, Mankato. It has been accepted for inclusion in All Graduate Theses, Dissertations, and Other Capstone Projects by an authorized administrator of Cornerstone: A Collection of Scholarly and Creative Works for Minnesota State University, Mankato. Steroidogenesis in the Green Anole Lizard Brain and Gonad By Christine Peek A Thesis Submitted in Partial Fulfillment of the Requirements for the Degree of Masters of Science In Biological Sciences Minnesota State University, Mankato Mankato, Minnesota August 15, 2017 (8/15/2017) Steroidogenesis in the Green Anole Lizard Brain and Gonad Christine Peek This thesis has been examined and approved by the following members of the student’s committee. Rachel Cohen Advisor Allison Land Committee Member David Sharlin Committee Member Abstract Seasonally breeding animals reproduce during certain times of the year and, subsequently, behaviors, steroid hormone levels, and brain morphology change.
    [Show full text]